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The amyloid-β degradation intermediate
Aβ34 is pericyte-associated and reduced in
brain capillaries of patients with
Alzheimer’s disease
Tunahan Kirabali1 , Serena Rigotti1, Alessandro Siccoli1, Filip Liebsch2,3, Adeola Shobo3, Christoph Hock1,4,
Roger M. Nitsch1,4, Gerhard Multhaup3 and Luka Kulic1,5*
Abstract
An impairment of amyloid β-peptide (Aβ) clearance is suggested to play a key role in the pathogenesis of sporadic
Alzheimer’s disease (AD). Amyloid degradation is mediated by various mechanisms including fragmentation by
enzymes like neprilysin, matrix metalloproteinases (MMPs) and a recently identified amyloidolytic activity of β-site
amyloid precursor protein cleaving enzyme 1 (BACE1). BACE1 cleavage of Aβ40 and Aβ42 results in the formation
of a common Aβ34 intermediate which was found elevated in cerebrospinal fluid levels of patients at the earliest
disease stages. To further investigate the role of Aβ34 as a marker for amyloid clearance in AD, we performed a
systematic and comprehensive analysis of Aβ34 immunoreactivity in hippocampal and cortical post-mortem brain
tissue from AD patients and non-demented elderly individuals. In early Braak stages, Aβ34 was predominantly
detectable in a subset of brain capillaries associated with pericytes, while in later disease stages, in clinically
diagnosed AD, this pericyte-associated Aβ34 immunoreactivity was largely lost. Aβ34 was also detected in isolated
human cortical microvessels associated with brain pericytes and its levels correlated with Aβ40, but not with Aβ42
levels. Moreover, a significantly decreased Aβ34/Aβ40 ratio was observed in microvessels from AD patients in
comparison to non-demented controls suggesting a reduced proteolytic degradation of Aβ40 to Aβ34 in AD. In
line with the hypothesis that pericytes at the neurovascular unit are major producers of Aβ34, biochemical studies
in cultured human primary pericytes revealed a time and dose dependent increase of Aβ34 levels upon treatment
with recombinant Aβ40 peptides while Aβ34 production was impaired when Aβ40 uptake was reduced or BACE1
activity was inhibited. Collectively, our findings indicate that Aβ34 is generated by a novel BACE1-mediated Aβ
clearance pathway in pericytes of brain capillaries. As amyloid clearance is significantly reduced in AD, impairment
of this pathway might be a major driver of the pathogenesis in sporadic AD.
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Introduction
Amyloid beta (Aβ) plaques with extracellular fibrillar de-
posits of Aβ peptide and neurofibrillary tangles (NFTs)
composed of phosphorylated tau represent the key histo-
pathological hallmarks of Alzheimer’s disease [22, 33, 58].
Aβ peptides are generated via sequential proteolytic cleav-
age of the amyloid precursor protein (APP) [47]. Initial
cleavage of APP by β-secretase generates a membrane-
bound C-terminal fragment of APP (β-CTF) [14, 66]
which is sequentially processed by γ-secretase resulting in
the formation of longer species, like Aβ40 and Aβ42/43,
in addition to several other C-terminally truncated Aβ
variants [39, 56]. A full set of Aβ isoforms with both N-
and C-terminally truncated Aβ species can be detected in
the human brain and cerebrospinal fluid (CSF) [28, 41, 42,
45, 62]. N-terminally truncated Aβ isoforms show an
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increased aggregation propensity and have previously been
associated with the deposition of dense-core amyloid pla-
ques in the brain [18, 35, 40, 46, 49, 51]. In contrast, C-
terminally truncated shorter Aβ isoforms show a higher
solubility in vitro and are more commonly detected in the
cerebral vasculature [11, 18, 28, 43]. One of the C-
terminally truncated isoforms, Aβ34, can be generated as
an intermediate of multiple degradation pathways includ-
ing Aβ degradation by the matrix metalloproteases
(MMP), MMP2 and MMP9 [25], as well as stepwise pro-
teolytic cleavage of both Aβ40 and Aβ42 by γ-secretase
[39]. In addition to its role as the major β-secretase in
APP processing, BACE1 (beta-site amyloid precursor pro-
tein cleaving enzyme 1) has been shown to cleave longer
Aβ isoforms at position 34 and this pathway has been
identified as the major source of Aβ34 [19, 50]. This add-
itional BACE1 mediated cleavage can only take place with
Aβ peptides as substrates implying that BACE1 indeed
acts as an Aβ40/42 degrading enzyme to generate Aβ34
[19, 50]. In a recent study, we were able to show that
Aβ34 levels are directly affected by over-expression or in-
hibition of BACE1 both in vitro and in vivo, and that cere-
bral BACE1 is the critical factor for Aβ34 generation [30].
Supporting its proposed role as a biomarker for clearance
in sporadic AD, CSF Aβ34 levels were found to be ele-
vated in subjects with mild cognitive impairment (MCI)
who later converted to AD dementia [30]. Moreover, we
also discovered a positive correlation between CSF Aβ34
levels and overall Aβ clearance rates in individuals with
biomarker evidence of cerebral amyloid deposition [30].
In the present study, we investigated the tissue dis-
tribution of the C-terminally truncated isoform Aβ34 in
post-mortem brain samples from healthy elderly in-
dividuals and AD patients of various AD neuropa-
thological stages according to Braak [8, 9]. Aβ34
immunoreactivity was detected exclusively in the vascu-
lature and was most prominent in brain capillaries of
healthy elderly individuals in the early Braak stages. In
AD patients and more advanced Braak stages, however,
this capillary associated Aβ34 immunoreactivity was
largely lost. Colocalization studies in postmortem brain
tissue and isolated human microvessels revealed a
unique association of Aβ34 with the platelet derived
growth factor receptor beta (PDGFR-β) which serves as
a marker for brain pericytes [1, 31]. Further in vitro
biochemical studies in cultured human primary peri-
cytes confirmed that the C-terminally truncated iso-
form Aβ34 is released by these cells via BACE1
mediated enzymatic cleavage of Aβ40. Collectively, the
results of our work suggest the existence of a novel
pericyte mediated Aβ clearance pathway, which gener-
ates Aβ34 as a stable intermediate. Early impairment of
this pathway may contribute to the overall reduced Aβ
clearance associated with sporadic AD [34].
Materials and methods
Post-mortem human samples
Paraffin-embedded hippocampus and middle-frontal
cortex (gyrus frontalis medius) tissue blocks and frozen
middle frontal cortex samples were provided by the
Netherlands Brain Bank (NBB), the Netherlands Insti-
tute for Neuroscience, Amsterdam, the Netherlands.
Post-mortem samples were collected from donors with
a written informed consent for a brain autopsy and the
use of the material for research purposes was obtained
by the NBB. Subjects’ demographics, neuropathological
and clinical evaluations are listed in Table 1. In brief,
subjects are classified according to their Braak stages
from stage I to VI [8, 9]. Age, gender, apolipoprotein E
(APOE) genotype, CERAD (Consortium to Establish a
Registry for Alzheimer’s Disease) score for amyloid load
and clinical diagnosis (non-demented control
(NDCNTRL) or AD patient (AD)) are provided for each
subject [27, 36].
Immunofluorescence staining
Sections of paraffin-embedded hippocampus and cortex
samples with 5 μm thickness were deparaffinized in
xylene and then rehydrated by immersing the slides in
order in 100% ethanol, 95% ethanol, 70% ethanol and
water. Sections were pretreated by boiling in 0.1M
sodium citrate buffer for antigen retrieval as previously
described [20]. Only for amyloid plaque staining, sec-
tions were also incubated in 95% formic acid for 5 min
prior to citrate buffer pre-treatment. Unspecific binding
sites were blocked with 10% horse serum in phosphate-
buffered saline (PBS) with 0.2% Triton X-100 (PBS-T).
After blocking, sections were incubated overnight at 4 °C
with primary antibodies diluted in 5% horse serum in
PBS-T. All primary antibodies and dilutions used in im-
munohistochemistry are listed in Additional file 1. After
washing with PBS, sections were incubated for 2 h at
room temperature with secondary antibodies (1:200 dilu-
tion in 5% horse serum in PBS-T, donkey anti-mouse/
rabbit/goat conjugated to Alexa488, Cy3, Alexa647 and
streptavidin conjugated to Alexa488) purchased from
Jackson Immunoresearch (Pennsylvania, USA). Follow-
ing the secondary antibody step, sections were incubated
for 10 min with 2 mg/ml DAPI (4′,6-diamidino-2-pheny-
lindole) (Sigma Aldrich, Missouri, USA) in PBS for nu-
cleus staining and for 5 min in 0.2% Sudan Black (Sigma
Aldrich) in 70% ethanol to quench auto-fluorescence
[38]. Coverslips were mounted with water based mount-
ing medium and slides were stored at 4 °C. Pictures were
taken with Leica DM4000B microscope or Leica TCS
SP8 confocal microscope. For peptide blocking/competi-
tion assay, 1 μg anti-Aβ34 and 1 μg anti-PDGFR-β anti-
bodies were pre-incubated with 10 μg recombinant
human Aβ34 peptide (Anaspec, California, USA) in 5%
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horse serum in PBS-T for 1 h. The immunohistochemis-
try protocol was then followed as described above.
Quantification of immunofluorescence staining
For each subject, 2 sections, which are at least 50 μm
apart from each other, were used and 10 pictures with
20X magnification were randomly taken per section. For
Aβ34 and PDGFR-β quantitative analyses, sections were
also stained with anti-Collagen IV antibody to allow a
quantification of the total number of vessels in each vis-
ual field. Vessels with Aβ34 or PDGFR-β immunoreac-
tivity were counted manually and divided by the total
number of vessels in the visual field assessed by Collagen
IV immunostaining. In order to quantify only capillaries,
vessels with a diameter > 10 μm were excluded. Mean of
20 visual fields were calculated for each subject and re-
sults were reported as percentage of Aβ34 or PDGFR-β
positive vessels. For tau tangle and amyloid plaque quan-
tifications, pictures were converted to 8-bit images and
constant thresholds were applied to each picture. Intra-
neuronal APP signal was also eliminated by using this
threshold in amyloid plaque quantification. The area for
each immunostained picture was calculated with ImageJ
and results were reported as percentage of amyloid or
tau positive area. Mean of 20 visual fields were calcu-
lated for each subject and reported in the figures.
Microvessel isolation and preparation of vessel enriched
brain lysates
Previously published microvessel isolation protocols for
mouse and rat brains were adapted for frozen human
brains [6, 10, 65]. Briefly, 1 g frozen human cortex was
placed in 5ml Hank’s balanced salt solution (HBSS) with
protease and phosphatase inhibitors and homogenized
with glass Teflon homogenizer (20 strokes at 400 rpm).
Homogenates were centrifuged at 2000 g for 10 min at
4 °C. The pellet was resuspended in 17.5% Dextran
(Sigma Aldrich) in PBS and centrifuged at 4400 g for 15
min at 4 °C. The pellet was again resuspended in 1 ml
HBSS and passed through filters with 100 μm and 20 μm
pore size (Pluriselect Life Science, Leipzig, Germany) in
the respective order. The material retained on the 20 μm
filter was collected by gentle washing with HBSS and
centrifuged at 2000 g for 10 min at 4 °C. The resulting
pellet (corresponding to microvessels) was resuspended
in 4% paraformaldehyde (PFA) in PBS for fixation. Simi-
lar to the immunofluorescence protocol, microvessels
were blocked with 10% horse serum in PBS-T and
Table 1 Characteristics of post-mortem human brain samples
Brain Region: Hippocampus (paraffin-embedded)
Braak Stage Number of Subjects Age at Deatha Genderb APOE4 Statusc CERAD Scored Diagnosise
I 6 79 ± 6.8 M (1) F (5) + (1), − (2) O(2), A(2), B(2) NDCNTRL
II 6 85.7 ± 1.8 M (1) F (5) + (2), − (4) A(1), B(3), C(2) NDCNTRL
III 6 82 ± 5.8 M (5) F (1) + (3), − (2) A(1), B(2), C(3) NDCNTRL
IV 7 92.3 ± 3.3 M (1) F (6) + (2), − (5) C NDCNTRL (2), AD(5)
V 4 82.3 ± 10.1 M (0) F (4) + (3), − (1) C AD
VI 6 86 ± 6.8 M (0) F (6) + (4), − (2) C AD
Brain Region: Cortex (paraffin-embedded)
Braak Stage Number of Subjects Age at Death Gender APOE4 Status CERAD Score Diagnosis
I 4 82.5 ± 9.3 M (2) F (2) + (0), − (4) A(1), B(2), C(1) NDCNTRL
II 3 85.3 ± 0.5 M (1) F (2) + (1), − (2) A(1), B(3), C(2) NDCNTRL
III 4 87 ± 3.7 M (3) F (1) + (2), − (2) A(1), B(2), C(3) NDCNTRL
IV 6 89.3 ± 5.4 M (2) F (4) + (3), − (3) B(2), C(4) NDCNTRL (2), AD (4)
V 3 84.3 ± 13.2 M (0) F (3) + (2), − (1) C AD
VI 5 89.2 ± 3.4 M (0) F (5) + (4), − (1) C AD
Brain Region: Cortex (frozen)
Braak Stage Number of Subjects Age at Death Gender APOE4 Status CERAD Score Diagnosis
I – II 4 88.7 ± 7.9 M (0) F (4) + (0), − (2) O(1), A(1), B(1), C(1) NDCNTRL
III – IV 5 91.4 ± 2.9 M (1) F (4) + (1), − (2) O(1), B(2), C(2) NDCNTRL (3), AD (2)
V – VI 5 75.2 ± 8.1 M (2) F (3) + (2), −(2) B(1), C(4) AD
a Age at death is reported as mean ± standard deviation
b M Male, F Female
c APOE4 Status +: APOE3/4 or APOE4/4, −:APOE3/3, APOE3/2, APOE2/2. APOE4 status were not available for some subjects
d CERAD Consortium to Establish a Registry for Alzheimer’s Disease
e NDCNTRL Non-demented control, AD Alzheimer’s disease patient
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incubated 2 h with primary antibodies and 2 h with sec-
ondary antibodies in PCR tubes at room temperature.
Microvessels were then placed on glass slides and cover-
slips were mounted with water-based mounting medium.
Images were taken with Leica TCS SP8 confocal micro-
scope. For vessel enriched brain lysates, material
retained on both filters was collected and combined by
washing with HBSS and centrifugation at 2000 g for 10
min at 4 °C. After centrifugation, the pellet was incu-
bated in RIPA buffer at 4 °C with rotation for 1 h, soni-
cated for 5 min in ultrasonic bath and then centrifuged
at 10000 g for 15 min at 4 °C. Supernatants were col-
lected and stored at -80 °C.
Immunoassays
Custom-made 4-plex (Aβ34, Aβ38, Aβ40, and Aβ42)
meso scale discovery (MSD) plates were purchased
from Meso Scale Diagnostics (Maryland, USA). For 1-
plex Aβ34 assay, high binding MSD plates were spot-
coated with monoclonal anti-Aβ34 antibody and
incubated overnight. The assay was performed accord-
ing to manufacturer’s instructions as previously re-
ported [30]. Briefly, diluent 35 was added into each well
and incubated for 1 h at room temperature for block-
ing. PBS with 0.2% Tween-20 was used for washing.
25 μl sample or standard and 25 μl sulfo-tag anti-
amyloid beta (6E10 or 4G8) detection antibody were
added. Plates were incubated at 4 °C overnight with
rigorous shaking. On the following day, 2X read buffer
was added after washing and plates were read with
SECTOR Imager 600 plate reader (Meso Scale Diagnos-
tics, USA) and analyzed with MSD Workbench soft-
ware (Meso Scale Diagnostics, USA).
The human total PDGFR-β enzyme-linked immuno-
sorbent assay (ELISA) and ELISA ancillary reagent kits
were purchased from R&D Systems (Minnesota, USA).
The assay was performed according manufacturer’s in-
structions. Briefly, plates were incubated with capture
antibody diluted in PBS overnight at 4 °C. PBS with 0.2%
Tween-20 was used for washing. Aliquots of 100 μl sam-
ple or standard were diluted in diluent 12 and incubated
for 2 h at room temperature. After washing, biotinylated
detection antibody, diluted in diluent 14, was added into
wells and incubated for 2 h at room temperature. Fol-
lowing a wash step, streptavidin-horseradish peroxidase
(HRP) substrate diluted in diluent 14 was added. Color
reagents were added and incubated for 20 min; the reac-
tion was stopped by adding stop solution (2 N sulfuric
acid) and absorbance at 520 nm was measured with
Tecan Infinite M Nano plate reader.
Cell culture
Human primary pericytes were purchased from Scien-
Cell (California, USA). Cells were maintained in Pericyte
Medium (ScienCell) with addition of 2% fetal bovine
serum (FBS) (ScienCell), penicillin/streptomycin (Scien-
Cell) and pericyte growth supplement (ScienCell) in
poly-L-lysine (ScienceCell or SigmaAldrich) coated T75
flasks. Cells from each passage were frozen in 10% di-
methyl sulfoxide (DMSO) in FBS and stored at -150 °C.
Cells from passage 3 to 6 were used in experiments.
For Aβ uptake assays, human recombinant Aβ40
(rPeptide, Watkinsville, USA) and mouse Aβ40 syn-
thetic peptides (Anaspec, California, USA) were pre-
pared according to published protocols [52]. Briefly,
lyophilized peptides were dissolved in hexafluoro-2-
propanol (HFIP) on ice and aliquoted into 1.5 ml
Eppendorf tubes. Aliquots were lyophilized and stored
at -80 °C. Before the experiment, lyophilized peptide
was dissolved in DMSO and concentration adjusted
with pericyte medium. Pericytes were cultured in either
60-mm dishes or 6-well plates and treated with differ-
ent concentrations of Aβ40 for varying incubation
times. At the end of the experiment cell lysates were
prepared in RIPA buffer, cell media were collected and
stored for further analysis. In order to block Aβ uptake,
cells were treated with 10 μM endocytosis blocker IPA3
(1,1′-Dithiodi-2-naphthtol) (Abcam, Cambridge, United
Kingdom) or 500 nM low density lipoprotein receptor-
related protein 1 (LRP1) blocker RAP (receptor associ-
ated protein) (R&D Systems) for 2 h prior to Aβ40
(2 μM) addition. Solutions of 10 μM IPA3 and 500 nM
RAP were used since these concentrations were re-
ported to reduce Aβ40 uptake without affecting cell
viability [61]. Cell lysates were prepared with RIPA buf-
fer, cell media were collected and stored for further
analysis. In order to study Aβ uptake, pericytes were
seeded on coverslips in a 24-well plate and incubated
with Hilyte Fluor 488-labeled human Aβ40 (Anaspec)
after RAP or IPA3 treatment. After fixation and DAPI
staining, cells were imaged with Leica TCS SP8 con-
focal microscope. For 96-well assay, pericytes were
plated in 96-wells and incubated with Hilyte Fluor 488-
labeled human Aβ40 after RAP or IPA3 treatment.
After washing, extracellular Aβ was quenched with
0.2% trypan blue fluorescence and measured at 485 nm
excitation and 535 nm emission wavelength for detec-
tion of Hilyte Fluor-488 with Tecan Spark plate reader.
Subsequently, cells were incubated with DAPI and
fluorescence was measured with 360 nm excitation and
485 nm emission wavelength to normalize Hilyte Fluor
488 fluorescence for cell count in each well. For BACE1
inhibition assays, pericytes were treated with varying
concentrations (10 μM, 5 μM, 2 μM, 1 μM) of BACE1
Inhibitor IV (Sigma Aldrich) for 12 h prior to Aβ40
(2 μM) addition. As in previous experiments, lysates
were prepared with RIPA buffer, cell media were col-
lected and stored for further analysis.
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Immunocytochemistry
Coverslips were coated with poly-L-lysine and placed
in 24-well plate. Cells were seeded in 24-well plates,
incubated overnight and then fixed with 4% PFA in
PBS. Unspecific binding was blocked with 10% horse
serum in PBS. Cells were incubated with primary
antibody for 2 h, followed by secondary antibody for
90 min at room temperature (Additional file 1). For
nucleus staining, cells were incubated with 2 mg/ml
DAPI solution in distilled water for 10 min. Then,
coverslips were transferred on slides with water-based
mounting medium. Cells were imaged with Leica
DM4000B microscope or Leica TCS SP8 confocal
microscope.
Western blot and immunoprecipitation
Pericyte lysates were mixed with 2X Novex SDS sample
buffer (Thermo Fisher Scientific, Massachusetts, USA)
containing 10% β-mercaptoethanol 1:1, incubated at
95 °C for 5 min and loaded on Novex 10–20% Tricine
gel (Thermo Fisher Scientific). Electrophoresis was per-
formed at 100 V for 2 h in Tricine running buffer. After
transfer, nitrocellulose membranes were blocked with
5% milk blocking solution and incubated with primary
antibodies at 4 °C overnight. On the next day, mem-
branes were incubated with HRP-coupled secondary
antibodies (Jackson Immunoresearch) diluted in 5% milk
blocking solution for 2 h at room temperature and devel-
oped with SuperSignal West Femto Maximum Sensitiv-
ity Substrate (ThermoFisher). Images were taken with
ImageQuant LAS 400 (GE Healthcare, Illinois, USA).
BACE1 immunoprecipitation was performed using mag-
netic separation with Dynabead M-280 Sheep Anti-
Rabbit IgG (Invitrogen) according to the manufacturer’s
protocol. Briefly, cell lysates were incubated with rabbit
anti-BACE1 antibody (ab2077, abcam) overnight at 4 °C
with gentle rotation. After addition of magnetic beads,
samples were incubated for 1 h with gentle rotation at
room temperature. After washing with PBS, beads were
magnetically separated and incubated in 2X Novex SDS
sample buffer containing 10% β-mercaptoethanol at
95 °C for 5 min. Beads were magnetically separated and
proteins loaded on Novex 10–20% Tricine gel. Electro-
phoresis and Western blotting were performed as de-
scribed above.
Statistical analysis
Graphpad Prism 8 software was used for all statistical
analyses. Assumption of normal (Gaussian) distribution
was tested with Shapiro-Wilk normality test (α = 0.05). If
the assumption of normality was true, the significance of
the differences between two groups was tested with a
two-tailed unpaired Student’s t test. The significance of
the differences between more than two groups was
tested with 1-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison test. Correla-
tions were calculated with Pearson’s correlation (α =
0.05, confidence interval 95%, two tailed). In case of a
deviation from normal distribution, the significance of
the differences between two groups was tested with a
two-tailed unpaired Mann-Whitney test. Correlations
were calculated with Spearman’s correlation (α = 0.05,
confidence interval 95%, two tailed). Correlation coeffi-
cients (r) and p-values were reported in the figures.
Results
Aβ34 immunoreactivity is detected in brain capillaries of
non-demented elderly individuals and this
immunoreactivity is progressively reduced in AD patients
In this study, we performed a comprehensive disease-
stage dependent immunohistochemical analysis of
Aβ34 immunoreactivity in hippocampal and cortical
brain tissue from cognitively intact elderly individuals
and AD patients of various Braak stages (Table 1).
Throughout disease stages, Aβ34 was predominantly
found in small vessels, which were identified as brain
capillaries based on their structure and diameter of < 10
um (Fig. 1a, Additional file 2a). Notably, these Aβ34
positive capillaries were free of fibrillar amyloid
(assessed by Thio S staining, Additional file 2b), and ca-
pillary congophilic amyloid angiopathy (CAA) was gen-
erally absent in the investigated sample. Moreover,
Aβ34 was not detectable in parenchymal amyloid pla-
ques, but was occasionally observed in colocalization
with arterial CAA deposits in a minority of the assessed
brain samples (Additional file 2b-c). To further quanti-
tatively assess the predominant Aβ34 immunoreactivity
in brain capillaries of AD patients and non-demented
control individuals, double immunofluorescence stain-
ing with the basement membrane marker collagen IV
was performed (Fig. 1b). The stainings revealed that in
non-demented elderly individuals up to 60–70% of ca-
pillaries showed immunoreactivity for Aβ34 (Fig. 1d).
In contrast, the proportion of Aβ34 positive capillaries
in patients with AD clinical diagnosis was strongly re-
duced (Fig. 1d), whereas the capillary density was not
significantly changed (Additional file 2d). A disease
stage dependent analysis of Aβ34 immunoreactivity in
the whole sample revealed a peak of Aβ34 immunore-
activity in the early Braak stages (highest percentage of
Aβ34 positive capillaries in Braak stage 2) and a dra-
matic loss of Aβ34 positive vessels between Braak
stages 3 and 4 (Fig. 1c). Interestingly, Aβ34 immunore-
activity negatively correlated both with amyloid plaque
load (Fig. 1e) and with tau pathology (Fig. 1f) in hippo-
campus and cortex; however, stronger effects were ob-
served for the association of Aβ34 with tau (Fig. 1).
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Aβ34 in capillaries colocalizes with pericytes which are
gradually lost in advanced disease stages
Having shown that Aβ34 in non-demented elderly indi-
viduals and in patients with AD was mainly associated
with brain capillaries, and that the percentage of Aβ34
immunoreactive vessels was progressively reduced in
advanced AD neuropathological stages, we determined
next in more details the exact localization of capillary
Aβ34 immunoreactivity within the neurovascular unit.
Double immunofluorescence stainings with basement
membrane marker Collagen IV (Fig. 2a), astroglial
marker glial fibrillary acidic protein (GFAP) (Fig. 2b),
Fig. 1 Capillary associated Aβ34 immunoreactivity is reduced in Alzheimer’s disease patients and inversely correlated with both amyloid and tau.
a Double immunostaining of vascular marker, Lectin (green), and Aβ34 (red) in human post-mortem brain. Merged image shows magnification of
the dashed area. (Scale bar 10 μm) b Representative images of double immunostaining of basement membrane marker, Collagen IV (green) and
Aβ34 (red) in a non-demented control and an AD patient for quantification of capillary Aβ34 immunoreactivity. In each visual field number of
Aβ34+ vessels divided by total number of vessels (diameter < 10 μm) (calculated with Collagen IV immunostaining) and results reported as
percentage of Aβ34+ vessels. (Scale bar 10 μm) c Braak-stage distribution for % of Aβ34+ vessels in hippocampus and cortex. Graphs represent
individual values and mean with standard deviation (SD). d Diagnosis-based distribution of % of Aβ34+ vessels in hippocampus and cortex.
Graphs represent individual values and mean with SD. **** (p < 0.001) was determined by a two-tailed unpaired student’s t test. e Correlation of
%Aβ34+ vessels with amyloid plaque load in hippocampus and cortex. Amyloid plaque load was calculated by using % area covered by
immunostaining of N-terminal anti-amyloid (clone W02) antibody. For hippocampus Pearson’s correlation (α = 0.05, CI 95%, two-tailed) and for
cortex Spearman’s correlation were (α = 0.05, CI 95%, two-tailed) used. f Correlation of %Aβ34+ vessels with tau tangles in hippocampus and
cortex. Tau+ area was calculated by using % area covered by anti-tau (clone AT8) antibody. Correlations were calculated using Spearman’s
correlation (α = 0.05, CI 95%, two-tailed)
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endothelial cell marker CD31 (Fig. 2c) and pericyte
marker PDGFR-β (Fig. 2b-c-d) were performed. These
analyses demonstrated a robust overlay of Aβ34 immu-
noreactivity with PDGFR-β, but not with CD31, nor with
GFAP, suggesting that Aβ34 was specifically localized in
brain pericytes (Fig. 2b-c-d). In line with these findings,
a close association was also observed with Collagen IV
which represents a major extracellular component of the
capillary basement membrane where pericytes reside
(Fig. 2a). Given the observed colocalization of Aβ34
immunoreactivity with brain pericytes within the neuro-
vascular unit and the above-mentioned disease-stage
dependent loss of Aβ34 positive capillaries in AD, we
hypothesized that the progressive decrease in Aβ34 po-
sitive capillaries in the course of AD could at least
partially be explained by the previously reported dys-
function and loss of brain pericytes in AD pathogenesis
[23, 48]. In agreement with this hypothesis, a strong
positive correlation could be established between the
percentage of Aβ34 positive and PDGFR-β immunoreac-
tive brain capillaries (Fig. 2e). The analysis of PDGFR-β
immunoreactivity across Braak stages revealed a gradual
loss of pericyte coverage starting already at Braak stage 2
(Fig. 2f). Similar to our results of the quantitative
Fig. 2 Aβ34 is associated with PDGFR-β + pericytes in small capillaries and Aβ34 immunoreactivity is strongly correlated with pericyte coverage a
Merged image of Aβ34 (green) and basement membrane marker, Collagen IV (red) immunostaining. (Scale bar 10 μm) b Merged image of
astrocyte marker, GFAP (green), Aβ34 (red) and pericyte marker, PDGFR-β (blue) immunostaining (Scale bar 20 μm). Insert shows magnification of
the dashed area. c Merged image of Aβ34 (green), endothelial cell marker, CD31 (red) and pericyte marker, PDGFR-β (blue) immunostaining
(Scale bar 20 μm). Insert shows magnification of the dashed area. d Maximum projection of confocal merged image of Aβ34 (green) and pericyte
marker PDGFR-β (red). (Scale bar 5 μm). e Correlation of % Aβ34+ vessels with % PDGFR-β + vessels in hippocampus and cortex. % of PDGFR-β +
vessels represents the number of PDGFR-β + vessels divided by total number of vessels assessed by Collagen IV immunostaining for each visual
field. For hippocampus Pearson’s correlation (α = 0.05, CI 95%, two-tailed), for cortex Spearman’s correlation were (α = 0.05, CI 95%, two-tailed)
used. f Braak stage distribution of %PDGFR-β + vessels (pericyte coverage) in hippocampus and cortex. Graphs represent mean with standard
deviation (SD). g Diagnosis-based distribution of %PDGFR-β + vessels in hippocampus and cortex. Graphs represent individual values and mean
with SD. **** (p < 0.001) was determined by a two-tailed unpaired Mann-Whitney test for hippocampus and student’s t-test for cortex
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assessments of Aβ34 immunoreactivity, the percentage
of PDGFR-β positive capillaries was significantly de-
creased in AD patients in comparison to non-demented
controls both in cortex and hippocampus (Fig. 2g).
Aβ34 is present in brain pericytes from isolated human
microvessels and its levels are correlated with pericyte
marker PDGFR-β in non-demented controls
Collectively, our immunohistochemical findings re-
vealed a predominant localization of Aβ34 in brain
capillaries and a robust colocalization and strong cor-
relation of Aβ34 with pericyte markers. Moreover, we
observed a progressive loss of capillary Aβ34 immuno-
reactivity across disease stages which was paralleled by
a gradual loss of pericyte coverage. To further investi-
gate the relationship between Aβ34 and its longer pre-
cursors, Aβ40 and Aβ42, as well as pericyte markers,
microvessels were isolated from frozen cortical samples
of healthy non-demented controls and AD patients
(Table 1). In line with the results of our immunohisto-
chemical analysis of human postmortem brain tissue,
immunofluorescence staining confirmed a colocaliza-
tion of Aβ34 immunoreactivity with pericyte marker
PDGFR-β and basement membrane marker Collagen IV
in the isolated microvessels (Fig. 3a). Similar to the
immunohistochemical findings, quantitative analysis of
RIPA-buffer extracted vessel enriched brain lysates
demonstrated a significant decrease in total PDGFR-β
levels in AD patients in comparison to non-demented
controls (Fig. 3b) and a positive correlation between
total PDGFR-β and Aβ34 levels in non-demented
individuals (Fig. 3c). Interestingly, a strong positive cor-
relation was recorded between the levels of vessel-
extracted Aβ34 and Aβ40, but not with Aβ42 (Fig. 3d).
A significantly decreased Aβ34/Aβ40 ratio was ob-
served in microvessels from AD patients in comparison
to non-demented controls suggesting a reduced proteo-
lytic degradation of Aβ40 to Aβ34 in AD (Fig. 3e).
Human primary pericytes are capable of degrading Aβ40
in a BACE1-dependent manner
Based on our findings in human post-mortem brain tis-
sue and in isolated microvessels, we hypothesized an
early involvement of brain pericytes in enzymatic Aβ
degradation leading to the generation of Aβ34 as an
intermediate, and a failure of this clearance pathway
with advancing disease stages in AD. We moreover ob-
served a positive correlation between Aβ34 and Aβ40 in
isolated human microvessels from non-demented elderly
individuals suggesting that Aβ40 could be the main sub-
strate for uptake and potential enzymatic degradation to
Aβ34 at the neurovascular unit. To assess whether peri-
cytes are capable of generating Aβ34 in vitro, uptake and
degradation of extracellularly applied Aβ40 were further
investigated in human primary pericyte cultures. As a
first step, expression of the Aβ uptake receptor, low
density lipoprotein receptor-related protein 1 (LRP1),
and of the major Aβ34 producing enzyme, BACE1, were
confirmed by immunocytochemistry and Western blot-
ting (Fig. 4a-b). In the following, human primary peri-
cytes were incubated with varying concentrations
(10 μM, 5 μM, 2.5 μM and 1 μM) of recombinant human
Aβ40 peptide for different treatment durations (12 h, 24
h, 36 h, 48 h). These experiments revealed a dose and
time dependent increase in Aβ34 levels both in cell ly-
sates and in cell media (Fig. 4c-d). In order to assess
whether Aβ34 generation in primary pericytes was
dependent on the uptake of extracellular Aβ40, cultures
were treated with either a generic endocytosis blocker,
IPA3, or with a specific LRP1 blocker, receptor associ-
ated protein (RAP). Treatment with both compounds
significantly reduced the uptake of fluorescently-labeled
Aβ40 in human primary pericytes (Additional file 3a-b).
Aβ34 levels in cell lysates were significantly reduced
when pericytes had been pre-incubated with IPA3 or
RAP before Aβ40 treatment (Fig. 4e) thus confirming
that internalization of extracellular Aβ40 is crucial for
Aβ34 generation in pericytes. In order to rule out the
possibility of an increased de novo synthesis of Aβ34 in
pericytes upon Aβ40 treatment, we further evaluated the
source of Aβ34 generated in the pericyte culture. For
this purpose, pericytes were treated with mouse Aβ40
and levels of Aβ34 were measured by using either a
mid-domain (clone 4G8) or an N-terminal (clone 6E10)
anti-amyloid detection antibody. The N-terminal anti-
body had previously been shown to be human specific
whereas the mid-domain antibody is known to detect
both human and murine Aβ isoforms [57]. After treat-
ment with mouse Aβ40, only the mid-domain antibody
was able detect the increase in Aβ34 levels while the N-
terminal, human Aβ specific, antibody failed to detect
any changes (Additional file 3c). The result of this ex-
periment therefore suggested that upon treatment with
mouse Aβ40, human pericytes predominantly generated
mouse Aβ34 via degradation of extracellularly applied
Aβ40. Enzymatic degradation of Aβ in pericytes was fur-
ther investigated upon pharmacological inhibition of the
major degrading enzyme. Since Aβ34 was identified as
an intermediate of BACE1-mediated enzymatic degrad-
ation and BACE1 expression could be confirmed in hu-
man primary pericyte culture, pericytes were treated
with varying concentrations (10 μM, 5 μM, 2 μM and
1 μM) of the BACE1 inhibitor IV, and Aβ34 levels were
assessed upon BACE 1 inhibition. Treatment of pericytes
with inhibitor IV prior to Aβ40 treatment led to a dose
dependent decrease in Aβ34 levels in pericytes (Fig. 4f)
supporting the role of BACE1 in Aβ34 generation in
pericytes. Consequently, our in vitro cell culture results
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demonstrate that Aβ34 can be generated as an inter-
mediate of BACE1-mediated enzymatic degradation of
internalized Aβ40 in pericytes.
Discussion
The C-terminally truncated Aβ isoform, Aβ34, has been
identified as an important intermediate product of
enzymatic Aβ degradation clearance. Although, in
principle, Aβ34 can be generated via various enzymatic
pathways, BACE1 was recently shown to be a major en-
zyme involved in Aβ34 generation in vivo [30]. In our
recently published study, we showed elevated CSF Aβ34
levels in early clinical stages of AD and a correlation of
CSF Aβ34 levels with Aβ clearance rates in subjects with
evidence of cerebral amyloid deposition [30]. In the
present study, we analyzed the distribution of Aβ34 in
post-mortem human brain samples to further investigate
its role in AD pathology and neurodegenerative disease
progression. Our comprehensive histological analysis re-
vealed a unique association of Aβ34 immunoreactivity
with pericytes in brain capillaries and a loss of this capil-
lary associated Aβ34 immunoreactivity with advancing
disease stages in AD patients. Interestingly, we observed
a peak in capillary Aβ34 immunoreactivity in the earlier
Fig. 3 Strong association between pericytes and Aβ34 in microvessels isolated from frozen human cortex. a Immunostaining of basement
membrane marker, Collagen IV (green), Aβ34 (red), pericyte marker, PDGFR-β (blue) and DAPI (blue) in a microvessel isolated from human cortex.
(Scale bar 20 μm). b Distribution of PDGFR-β levels (normalized to total protein content) in vessel enriched brain lysates for non-demented
controls and AD patients. Graph represent individual values and mean with SD. * (p < 0.05) was determined by a two-tailed unpaired student’s t
test. c Correlation of Aβ34 and PDGFR-β levels (normalized to total protein content) in vessel enriched brain lysates in non-demented controls
and AD patients. Correlations were calculated using Pearson’s correlation (α = 0.05, CI 95%, two-tailed). d Correlation of Aβ34 and Aβ40 or Aβ42
levels (normalized to total protein content) in vessel enriched brain lysates. For Aβ34 and Aβ40 correlation, Spearman’s correlation (α = 0.05, CI
95%, two-tailed) was used. For Aβ34 and Aβ42 correlation, Pearson’s correlation (α = 0.05, CI 95%, two-tailed) was used. e Distribution of Aβ34/
Aβ40 ratio in vessel enriched brain lysates for non-demented controls and AD patients. Graph represent individual values and mean with SD. **
(p < 0.01) was determined by a two-tailed unpaired Mann-Whitney test
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Braak stages (stage 2–3) which then dramatically de-
creased between Braak stages 3 and 4. The correlation of
Braak stages with cognitive scores used in clinical prac-
tice had been investigated by several previous studies
suggesting that individuals with MCI were most likely
distributed between Braak stages 2 and 4 [3, 21, 63].
Based on our current data, however, a definitive conclu-
sion whether the observed increase in capillary Aβ34 im-
munoreactivity in the earlier Braak stages indeed
represents a histopathological correlate of elevated CSF
Aβ34 levels detected in the recently published pro-
dromal AD clinical sample [30] cannot be drawn at this
point. On the one hand, we were not able to assess CSF
Aβ34 levels in our post-mortem cohort. On the other
hand, the post-mortem neuropathological sample was
clinically divided only into two diagnostic categories, i.e.
AD dementia and non-demented controls, the latter
including both healthy elderly individuals and non-
demented controls meeting the clinical criteria for a
mild cognitive impairment. Another limitation of our
study sample was the lack of younger individuals and
age-matched controls of even earlier Braak stages (Braak
stage 0) mainly due to the low prevalence and unavail-
ability of this control group [37]. Analysis of such add-
itional samples may be particularly helpful in clarifying
the question whether pericyte mediated Aβ degradation
occurs already at a very early stage in the absence of
overt AD pathology, and whether it is upregulated in an
age-dependent manner.
In our study, we provided substantial histological and
biochemical evidence for an association of Aβ34 with
brain pericytes. In vitro mechanistic assessments more-
over revealed that pericytes can generate Aβ34 by uptake
and degradation of extracellular Aβ40. Nevertheless, the
Fig. 4 Human primary pericytes take up extracellular Aβ40 via LRP1-mediated endocytosis and generate Aβ34 via BACE1-mediated enzymatic
degradation. a Immunostaining of human primary pericytes with PDGFR-β, LRP1, BACE1 and DAPI (blue). (Scale bar 10 μm) b Levels of PDGFR-β
and LRP1 in pericyte lysates from different passages (passage 4 (P4), passage 5 (P5) and passage 6 (P6)) assessed by western blot. Levels of BACE1
in pericyte lysate were also assessed by western blot following immunoprecipitation (IP). c Aβ34 levels in cell lysate and medium following 3 days
incubation with varying concentrations of human recombinant Aβ40 peptide. Aβ34 levels were normalized and shown as fold-change compared
to lowest concentration of Aβ40 treatment (1 μM). d Aβ34 levels in cell lysate and medium following incubation with 5 μM human recombinant
Aβ40 peptide for varying durations. Aβ34 levels were normalized and shown as fold-change compared to shortest duration of Aβ40 treatment
(12 h). e Aβ34 levels in cell lysate and medium following 2 h incubation with 10 μM IPA3 or 500 nM RAP prior to 12 h incubation with 2 μM Aβ40.
Aβ34 levels were normalized and shown as fold-change compared to only Aβ40 treated cells. f Aβ34 levels in cell lysate and medium following
12 h incubation with varying concentrations of BACE1 inhibitor (Inhibitor IV) prior to 12 h incubation with 2 μM Aβ40. Aβ34 levels were
normalized and shown as fold-change compared to only Aβ40 treated cells. The graphs (c-f) represent the mean ± SD. **** (p < 0.0001), *** (p <
0.001), ** (p < 0.01) and * (p < 0.05) were determined by 1-way ANOVA followed by Tukey’s multiple comparison test
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results of these experiments do not exclude the possibil-
ity that Aβ34 is generated elsewhere, e.g. in neurons,
and ultimately only taken up by pericytes for further
degradation. As a major Aβ source and the primary cell
type expressing BACE1 in the brain [5], neurons highly
likely represent an alternative source of Aβ34 generation
in the central nervous system. This assumption is also
supported by a previous study reporting intraneuronal
Aβ34 immunoreactivity [12]. The detection of capillary
Aβ34 immunoreactivity, however, may in our opinion be
better explained by an in situ production of Aβ34 in
pericytes. Due to its short half-life and its susceptibility
to further enzymatic degradation [11, 30], it appears ra-
ther unlikely that neuronal Aβ34 would reach the micro-
vasculature in sufficient amounts in order to be taken up
by brain pericytes. We rather propose that the more
stable and more abundant Aβ isoforms like Aβ40 and
possibly also Aβ42 which were previously shown to be
drained along vascular clearance routes [59, 60] are
taken up by pericytes and locally degraded to Aβ34 at
the neurovascular unit. In line with this assumption, our
mechanistic studies in human primary pericytes demon-
strated that pericytes are fully capable of taking up and
degrading Aβ40 to Aβ34. We did not specifically assess
whether Aβ42 can also be degraded to Aβ34 by pericytes
in vitro since the previously reported relative abundance
of Aβ40 at the vasculature compared to Aβ42 [26, 53,
59] and our correlative analyses and findings in the
human microvessels would rather be in line with Aβ40
being the major Aβ34 precursor in vivo. However, earl-
ier studies illustrated that Aβ42 is also a substrate of
BACE1 [19, 30] hence pericyte-associated Aβ34 could be
generated via BACE1-mediated degradation of Aβ42.
Both Aβ40 and Aβ42 fibrils were reported to induce
pericyte death in vitro; nevertheless Aβ34 was shown
not to aggregate even in high concentrations [11] and
did not show any deleterious effects in our pericyte cul-
ture experiments (data not shown). Previously, Caillava
et al. even suggested a protective role for this isoform
since Aβ34 treatment lowered the apoptotic cell death in
HEK cells in vitro [12]. Considering susceptibility of this
isoform to further enzymatic degradation by metallo-
proteases [12, 30], we suggest that BACE-1 mediated
degradation of Aβ40 or Aβ42 would enhance both en-
zymatic and vascular clearance by generating more ac-
cessible, benign and likely protective against apoptosis,
isoform Aβ34.
The increase in Aβ34 immunoreactivity which we ob-
served in our post-mortem sample may reflect a com-
pensatory upregulation of vascular Aβ degradation in
the early (preclinical or prodromal) stages of AD. As
mentioned above, such an upregulation of Aβ34-related
degradation clearance could provide an explanation for
the observed increase in CSF Aβ34 levels in patients
with prodromal AD [30]. As an alternative, elevated CSF
Aβ34 levels might also be explained by an unspecific re-
lease of Aβ34 by degenerating cells, which in our case
would be pericytes. We could not fully address with our
cross-sectional correlative postmortem study design,
whether the loss of Aβ34 immunoreactivity is caused by
the physical loss of pericytes during disease progression.
The decrease in Aβ34+ vessels appeared to be more pro-
nounced than the decrease in the percentage of PDGFR-
β + capillaries with advancing disease stages, suggesting
in addition to the loss of pericytes, a functional impair-
ment might have contributed to the observed findings.
Nevertheless, the robust positive correlation between
Aβ34 and PDGFR-β immunoreactivity in the brain and
levels in our microvessel preparations support that at
least partially an early loss of pericytes could be an im-
portant factor. In that regard, Aβ34 could also represent
a sensitive candidate marker reflecting impairments in
cerebrovascular pericyte function.
In the present study, we occasionally observed Aβ34
immunoreactivity in association with CAA in arterioles
and large arterial vessels. However, only a limited num-
ber of individuals in our sample set showed CAA path-
ology, and capillary CAA (capCAA) was completely
absent (Additional file 4). Wisniewski et al. previously
reported presence of Aβ fibrils in cerebral vessels associ-
ated with pericytes [64]; due to a lack of capillary CAA
cases we were unfortunately not able to assess the asso-
ciation between Aβ34 and aggregated Aβ forms in capil-
laries in our study. In case of arterial CAA, we speculate
that Aβ34 immunoreactivity in these arteries might be
the result of binding of this isoform to deposited vascu-
lar amyloid in arterial walls, e.g. upon failed vascular
drainage. Alternatively, Aβ34 could also be locally gener-
ated in CAA-laden vessels, e.g. through the proteolytic
cleavage of longer Aβ isoforms by BACE1 or MMPs [19,
25]. In support of this hypothesis, elevated levels of vas-
cular BACE1 were previously described in CAA-laden
arteries [7, 13, 16]. Further studies focusing on CAA and
vascular amyloidosis in samples including capCAA will
be required to obtain a better understanding of the ori-
gin of Aβ34 in CAA-affected arteries.
Pericytes have vital roles in vascular development, for-
mation and maintenance of the blood brain barrier
(BBB), blood flow regulation as well as in modulating
immune reactions in the brain [1, 2, 4, 15, 29]. In
addition, it has recently been shown that pericytes can
take up extracellular Aβ42 via a LRP1/ APOE dependent
mechanism in vitro [32]. Pericyte deficiency was shown
to worsen AD pathology in transgenic animals with en-
hanced Aβ levels in the brain; conversely, pericyte im-
plantation improved clearance of Aβ and reduced Aβ
deposition [44, 55]. Given their location in the intra-
mural periarterial drainage pathways and their ability to
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take up and degrade extracellular Aβ, pericytes have
been implicated to have a role in Aβ clearance [17, 24].
We have shown, for the first time, an association of
these cells with an important intermediate product of
Aβ clearance. Our results are thus in line with the
emerging role of pericytes in enzymatic Aβ degradation
in human brain [32]. A failure of the pericyte-mediated
Aβ degradation pathway could result in a progressive
loss of vascular Aβ clearance, enhanced Aβ40 accumu-
lation in the vasculature and consecutive impact on
parenchymal Aβ clearance and deposition. The strong
inverse association between Aβ34 immunoreactivity
and tau pathology which we detected in our post-
mortem sample suggests that this clearance pathway
may have tremendous impact on neurodegenerative
processes associated with AD.
Conclusions
In the present study were able to show a unique associ-
ation of the Aβ degradation intermediate Aβ34 with
brain pericytes in capillaries of non-demented elderly in-
dividuals and patients with manifest AD dementia. The
observed loss of pericytic Aβ34 in AD suggests an early
failure of this novel Aβ clearance pathway at the neuro-
vascular unit. Collectively, our findings strengthen the
role of the vascular system in early AD and provide fur-
ther support for a key role of brain pericytes in Aβ clear-
ance and disease pathogenesis [30, 54].
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